JAMES EAKIN: Open Payments
NPI 1023688769 · YAKIMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$378 in 16 payments from 8 companies in 2025. Trend: 2023 $75 · 2024 $117 · 2025 $378
Food & beverage: $378
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 6 | $107 |
| Janssen Pharmaceuticals, Inc | 2 | $65 |
| E.R. Squibb & Sons, L.L.C. | 2 | $62 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Neuronetics, Inc. | 1 | $19 |
Products named: Qelbree, INVEGA SUSTENNA, COBENFY, AUSTEDO XR, INGREZZA, REXULTI, Auvelity, NEUROSTAR TMS THERAPY SYSTEM.
Industry payments across WA — which companies pay providers there.
